Healthcare

U.S. Digital Therapeutics Market Size To Cross USD 12.09 Bn By 2030

The U.S. digital therapeutics market size accounted for US$ 2.05 Bn in 2022 and is projected to reach around USD 12.09 Bn by 2030, growing at a CAGR of 24.85% from 2022 to 2030.

U.S. Digital Therapeutics Market Size 2022 To 2030

Report Summary

The global U.S. digital therapeutics market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the U.S. digital therapeutics market across the globe.

A comprehensive estimate on the U.S. digital therapeutics market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of U.S. digital therapeutics during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2410

U.S. Digital Therapeutics Market Report Scope 

Report CoverageDetails
Market Size in 2022USD 2.05 Billion
Market Size by 2030USD 12.09 Billion
Growth Rate from 2022 to 2030CAGR of 24.85%
Base Year2021
Forecast Period2022 to 2030

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized U.S. digital therapeutics market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: Enterprise Artificial Intelligence Market Size To Cross USD 102.9 Bn By 2030

Market Players

The report includes the profiles of key U.S. digital therapeutics market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Omada Health Inc.
  • 2Morrow Inc.
  • Teladoc Health, Inc
  • Pear Therapeutics (U.S), Inc.
  • Fitbit Health Solutions
  • Welldoc, Inc
  • Click Therapeutics
  • Noom, Inc.
  • Akili, Inc.
  • Better Therapeutics, Inc

U.S. Digital Therapeutics Market Segmentation

By Application 

  • Diabetes
  • Obesity
  • Central Nervous System Diseases
  • Cardiovascular Disease (CVD)
  • Respiratory Disease
  • Smoking Cessation
  • Gastrointestinal Disorder (GID)
  • Others

By Product 

  • Software
  • Device

By End Use 

  • Patients
  • Providers
  • Payers
  • Employers
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Digital Therapeutics Market 

5.1. COVID-19 Landscape: U.S. Digital Therapeutics Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global U.S. Digital Therapeutics Market, By Application

8.1. U.S. Digital Therapeutics Market, by Application, 2022-2030

8.1.1 Diabetes

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Obesity

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Central Nervous System Diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Cardiovascular Disease (CVD)

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Respiratory Disease

8.1.5.1. Market Revenue and Forecast (2017-2030)

8.1.6. Smoking Cessation

8.1.6.1. Market Revenue and Forecast (2017-2030)

8.1.7. Gastrointestinal Disorder (GID)

8.1.7.1. Market Revenue and Forecast (2017-2030)

8.1.8. Others

8.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global U.S. Digital Therapeutics Market, By Product

9.1. U.S. Digital Therapeutics Market, by Product, 2022-2030

9.1.1. Software

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Device

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global U.S. Digital Therapeutics Market, By End Use 

10.1. U.S. Digital Therapeutics Market, by End Use, 2022-2030

10.1.1. Patients

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Providers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Payers

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Employers

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global U.S. Digital Therapeutics Market, Regional Estimates and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Forecast, by Application (2017-2030)

11.1.2. Market Revenue and Forecast, by Product (2017-2030)

11.1.3. Market Revenue and Forecast, by End Use (2017-2030)

Chapter 12. Company Profiles

12.1. Omada Health Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. 2Morrow Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Teladoc Health, Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Pear Therapeutics (U.S), Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Fitbit Health Solutions

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Welldoc, Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Click Therapeutics

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Noom, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Akili, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Better Therapeutics, Inc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Show More

Related Articles

Back to top button